Form 4: Supernus Pharmaceuticals Director Georges Gemayel Reports Stock Transactions

Director Georges Gemayel reports the acquisition and disposal of Supernus Pharmaceuticals (SUPN) common stock and stock options on September 13, 2024.

Summary

• On September 13, 2024, Georges Gemayel, a director of Supernus Pharmaceuticals, engaged in multiple transactions involving the company's common stock.
• Gemayel sold 3,886 shares of common stock at a weighted average price of $31.33.
• He also exercised a director stock option to acquire 10,000 shares at $11.46 per share.
• Following these transactions, Gemayel directly owns 23,315 shares of Supernus Pharmaceuticals common stock.
• Gemayel also disposed of 10,000 shares of common stock at a weighted average price of $31.33.
• He continues to hold 25,000 director stock options.

Sentiment

Score: 5

Explanation: Neutral sentiment. The transactions are a mix of buying (option exercise) and selling, suggesting no strong positive or negative signal.

Positives

• The exercise of stock options demonstrates the director's confidence in the company's future.

Negatives

• The sale of shares by a director could be interpreted negatively by some investors.

Risks

• Further sales of shares by insiders could put downward pressure on the stock price.

Industry Context

Insider transactions are routinely monitored by investors as they can provide signals, though not always definitive, about a company's prospects. It's important to consider the totality of insider activity, not just a single transaction.

Comparison to Industry Standards

• Comparing Gemayel's transactions to those of other directors in similar pharmaceutical companies could provide context, but this would require a broader analysis of SEC filings from peer companies such as Jazz Pharmaceuticals, or Alkermes.
• Typical insider trading activity is often benchmarked against historical trading patterns within the same company to determine if the current activity is unusual.

Stakeholder Impact

• The transactions could have a minor impact on shareholder sentiment, depending on how they are interpreted.

Key Dates